TA
BCRX icon

Tamarack Advisers’s BioCryst Pharmaceuticals BCRX Stock Holding History

Tamarack Advisers’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-125,000
Closed -$2.03M – 44
2022
Q1 		$2.03M Buy
+125,000
New +$2.01M 0.96% 30

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Tamarack Advisers's BCRX Position: Q2 2022 in Review

Tamarack Advisers sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2022, closing a stake of 125,000 shares — an estimated $2.03M sold.

Tamarack Advisers first reported a position in BCRX in Q1 2022 and held it in 1 quarter. The position peaked at $2.03M in Q1 2022. 221 funds tracked by Wall St. Rank hold BCRX as of Q2 2022.

  • Tamarack Advisers reported no remaining BioCryst Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Tamarack Advisers sold 125,000 BioCryst Pharmaceuticals shares in Q2 2022, an estimated $2.03M.
  • Tamarack Advisers first reported a position in BioCryst Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Tamarack Advisers's BioCryst Pharmaceuticals position peaked at $2.03M in Q1 2022.
  • 221 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2022.

Based on Tamarack Advisers's 13F filing for Q2 2022, filed 16 Aug 2022.